Send InquiryMenactra Meningococcal Polysaccharide Vaccine
Menactra Meningococcal Polysaccharide Vaccine Specification
- Formulations Type
- Injection
- Dosage
- Single dose of 0.5 ml via intramuscular injection
- Indication
- For individuals at risk of invasive meningococcal disease
- Storage Instructions
- Store at 2°C to 8°C; do not freeze
- Product Type
- Meningococcal Polysaccharide Vaccine
- Treatments & Functions
- Active immunization against meningococcal diseases
- Suitable For
- Children (2 years and above), adolescents, adults up to 55 years
- Age Group
- 2 years to 55 years
- Volume
- 0.5 ml per dose
- Shelf Life
- 24 months
- Regulatory Status
- WHO prequalified, licensed in multiple countries
- Contraindications
- Previous severe allergic reaction to any component of the vaccine or to a previous dose
- Common Side Effects
- Pain at injection site, redness, swelling, headache, malaise, fever
- Route of Administration
- Intramuscular
- Prescription Status
- Prescription Only Medicine (POM)
About Menactra Meningococcal Polysaccharide Vaccine
Menactra meningococcal polysaccharide vaccine
Meningococcal vaccine is a vaccine used against Neisseria meningitidis, a bacterium that causes meningitis, meningococcemia, septicemia, and rarely carditis, septic arthritis, or pneumonia. Mencevax (GlaxoSmithKline) and NmVac4-A/C/Y/W-135 (JN-International Medical Corporation) are used worldwide, but have not been licensed in the United States.
The first meningococcal conjugate vaccine (MCV4), Menactra, was licensed in the U.S. in 2005 by Sanofi Pasteur; Menveo, was licensed in 2010 by Novartis. Both MCV4 vaccines have been approved by the Food and Drug Administration (FDA) for people 2 through 55 years of age. In April 2011, Menactra received FDA approval for use in children as young as 9 months, although the Centers for Disease Control and Prevention (CDC) has not made recommendations for or against its use in children less than 2 years.
Comprehensive Protection Against Meningococcal Disease
Menactra provides robust and proven immunization against invasive meningococcal infections. Especially recommended for children, adolescents, and adults up to 55 years, this single-dose vaccine offers peace of mind for those at elevated risk, including travelers and students.
Safety and Regulatory Assurance
With WHO prequalification and licensing in numerous countries, Menactra meets stringent international safety and efficacy standards. It is available in India via authorized suppliers, wholesalers, and distributors, ensuring access to quality-assured healthcare solutions.
Simple Storage and Administration
Menactra comes in a ready-to-use 0.5 ml injectable formulation for intramuscular administration. The vaccine retains its stability for 24 months when stored at 2C to 8C, simplifying logistics for healthcare providers and ensuring vaccine potency.
FAQs of Menactra Meningococcal Polysaccharide Vaccine:
Q: How is Menactra vaccine administered?
A: Menactra is given as a single 0.5 ml dose via intramuscular injection, typically administered by a healthcare professional into the muscle of the upper arm or thigh.Q: What is the recommended age group for receiving Menactra?
A: Menactra is suitable for children from 2 years of age, adolescents, and adults up to 55 years old who are at risk of meningococcal disease.Q: What are the common side effects after receiving Menactra?
A: Common side effects include pain, redness, or swelling at the injection site, as well as headache, general malaise, and fever. These are usually mild and short-lived.Q: When is Menactra contraindicated?
A: Menactra should not be used in individuals who have experienced a severe allergic reaction to any component of this vaccine or to a prior dose.Q: What are the storage requirements for Menactra vaccine?
A: Menactra should be stored refrigerated between 2C and 8C. It must not be frozen to maintain its effectiveness.Q: Where can Menactra vaccine be sourced in India?
A: Menactra is available through authorized dealers, distributors, exporters, suppliers, traders, and wholesalers across India, ensuring widespread and regulated access.Q: What benefits does Menactra offer?
A: Menactra provides active immunization against invasive meningococcal diseases, reducing the risk of severe illness in individuals at increased exposure risk.
Get Latest Price
Price:
- 50
- 100
- 200
- 250
- 500
- 1000+
More Products in Vaccine And Injections Category
Vorizol Injection
Price 3000 INR / Box
Minimum Order Quantity : as per requirement Box
Feature : Other , Broadspectrum antifungal, rapid onset of action
Treatments & Functions : Other, Treatment of serious fungal infections
Product Type : Pharmaceutical Injection
Volume : 200 mg/vial
Celtere 80 mg Injection
Price 300 INR / Box
Minimum Order Quantity : as per requirement Box
Feature : Other , Sterile, singledose vial
Treatments & Functions : Other, Anti Cancer
Product Type : Injection
Volume : 80 mg/vial
Neulastim Injection
Price 425 INR / Piece
Minimum Order Quantity : as per requirement Piece
Feature : Other , Longacting; single fixeddose per cycle; reduces infectionrelated complications of chemotherapy.
Treatments & Functions : Other, Stimulates production of neutrophils to reduce risk of infection during chemotherapy.
Product Type : Injection
Volume : 6 mg/0.6 ml
Rhoclone Injection
Feature : Other, Other
Treatments & Functions : Other, Prevention of Rh isoimmunization in Rhnegative individuals exposed to Rhpositive blood such as during pregnancy or transfusion
Product Type : Injection
Volume : Varies depending on dosage; typically available in 300 mcg (1500 IU) or 100 mcg (500 IU) per vial
&
We are accepting bulk order quantity.
Developed and Managed by Infocom Network Private Limited.
